Both companies are benefiting from the obesity drug theme, but one stock looks much more attractive than the other.

Here's how we employ swing trading strategies of selling into strength, selling into weakness and cutting a loss quickly.

Aktis Oncology (AKTS) stock surged after an upsized Nasdaq IPO aimed at raising ~$318M with the help of its partner Eli Lilly ...

Highly rated Eli Lilly stock is this week's Big Cap 20 pick to watch as it attempts to take out a flat-base buy point.

Eli Lilly and Company (NYSE:LLY) operates as a global pharmaceutical firm focused on discovering, developing, manufacturing, ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

Schrödinger (SDGR) stock and Revvity (RVTY stock are in focus as firms join Eli Lilly (LLY) to integrate their software with ...

Aktis Oncology Inc. shares jumped 24 percent in their trading debut after the clinical-stage biotechnology company raised ...

In 2025 alone, MSD acquired infectious disease specialist Cidara Therapeutics for $9.2 billion, respiratory drug developer ...